- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | Passage BIO, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.07. | Passage BIO, Inc. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 25.06. | Remix Therapeutics to go public in reverse merger with once high-flying Passage Bio | 2 | BioPharma Dive | ||
| 24.06. | Spurned by FDA, Passage Bio finds exit through merger with Remix Therapeutics | 2 | FierceBiotech | ||
| PASSAGE BIO Aktie jetzt für 0€ handeln | |||||
| 24.06. | Passage Bio fusioniert mit Remix Therapeutics im Rahmen eines Aktientauschs | 1 | Investing.com Deutsch | ||
| 24.06. | Passage Bio to merge with Remix Therapeutics in all-stock deal | 2 | Investing.com | ||
| 24.06. | Passage Bio, Remix Therapeutics announce merger agreement | 2 | Seeking Alpha | ||
| 24.06. | Passage BIO, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.06. | Passage Bio and Remix Therapeutics Announce Merger Agreement | 639 | GlobeNewswire (Europe) | Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix's... ► Artikel lesen | |
| 26.05. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.05. | Passage BIO, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news | 1 | Investing.com | ||
| 21.04. | Regulatorischer Rückschlag: Oppenheimer halbiert Kursziel für Passage Bio | 3 | Investing.com Deutsch | ||
| 21.04. | Oppenheimer cuts Passage Bio stock price target on regulatory setback | 1 | Investing.com | ||
| 21.04. | Chardan downgrades Passage Bio stock rating on strategic review | 1 | Investing.com | ||
| 21.04. | Passage Bio: Chardan stuft Aktie nach strategischer Überprüfung auf 'Neutral' herab | 1 | Investing.com Deutsch | ||
| 20.04. | Lucid downgrades Passage Bio stock rating on funding concerns | 19 | Investing.com | ||
| 20.04. | Why Is Passage Bio Stock Falling In Pre-market? | 15 | RTTNews | ||
| 20.04. | Passage Bio reports biomarker improvements in FTD trial | 2 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| EXELIXIS | 46,940 | -0,10 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial |
Das Unternehmen PASSAGE BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,600 Euro und damit +1,77 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASSAGE BIO INC finden Sie auf Wallstreet Online.